IL92952A - R-enantiomers of n-propargyl-1-aminoindan compounds, their preparation and pharmaceutical compositions containing them - Google Patents

R-enantiomers of n-propargyl-1-aminoindan compounds, their preparation and pharmaceutical compositions containing them

Info

Publication number
IL92952A
IL92952A IL9295290A IL9295290A IL92952A IL 92952 A IL92952 A IL 92952A IL 9295290 A IL9295290 A IL 9295290A IL 9295290 A IL9295290 A IL 9295290A IL 92952 A IL92952 A IL 92952A
Authority
IL
Israel
Prior art keywords
propargyl
aminoindan
pai
mao
pharmaceutical composition
Prior art date
Application number
IL9295290A
Other languages
English (en)
Other versions
IL92952A0 (en
Inventor
Moussa B H Youdim
John P M Finberg
Ruth Levy
Jeffrey Sterling
David Lerner
Tirtsah Berger-Paskin
Haim Yellin
Original Assignee
Teva Pharma
Technion Res & Dev Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=11060756&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL92952(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teva Pharma, Technion Res & Dev Foundation filed Critical Teva Pharma
Priority to IL9295290A priority Critical patent/IL92952A/en
Publication of IL92952A0 publication Critical patent/IL92952A0/xx
Priority to IE437690A priority patent/IE62371B1/en
Priority to HU051/90A priority patent/HU215451B/hu
Priority to AU67724/90A priority patent/AU630772B2/en
Priority to CA002031714A priority patent/CA2031714C/en
Priority to ZA909997A priority patent/ZA909997B/xx
Priority to RO146581A priority patent/RO107552B1/ro
Priority to JP2409285A priority patent/JP2987453B2/ja
Priority to EP91100081A priority patent/EP0436492B1/en
Priority to SU914894485A priority patent/RU2001614C1/ru
Priority to DE69102288T priority patent/DE69102288T2/de
Priority to DK91100081.8T priority patent/DK0436492T3/da
Priority to AT91100081T priority patent/ATE106860T1/de
Priority to ES91100081T priority patent/ES2057604T3/es
Priority to SK6-91A priority patent/SK280742B6/sk
Priority to CS19916A priority patent/CZ288222B6/cs
Priority to US08/063,455 priority patent/US5387612A/en
Priority to US08/198,205 priority patent/US5457133A/en
Priority to US08/255,046 priority patent/US5453446A/en
Publication of IL92952A publication Critical patent/IL92952A/en
Priority to DE200512000045 priority patent/DE122005000045I1/de
Priority to US08/411,398 priority patent/US5532415A/en
Priority to US08/446,439 priority patent/US5744500A/en
Priority to US08/458,645 priority patent/US5668181A/en
Priority to US08/459,402 priority patent/US5576353A/en
Priority to US08/465,787 priority patent/US5599991A/en
Priority to US08/470,161 priority patent/US5786390A/en
Priority to US08/466,069 priority patent/US5519061A/en
Priority to US08/466,250 priority patent/US5891923A/en
Priority to HK98107147A priority patent/HK1008017A1/en
Priority to US10/305,478 priority patent/US6956060B2/en
Priority to US11/155,864 priority patent/US20060094783A1/en
Priority to NL300206C priority patent/NL300206I1/nl
Priority to LU91195C priority patent/LU91195I2/fr
Priority to US11/595,726 priority patent/US20070100001A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/26—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
    • C07C211/30—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring the six-membered aromatic ring being part of a condensed ring system formed by two rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/33—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C211/39—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton
    • C07C211/41—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems
    • C07C211/42—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems with six-membered aromatic rings being part of the condensed ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IL9295290A 1990-01-03 1990-01-03 R-enantiomers of n-propargyl-1-aminoindan compounds, their preparation and pharmaceutical compositions containing them IL92952A (en)

Priority Applications (34)

Application Number Priority Date Filing Date Title
IL9295290A IL92952A (en) 1990-01-03 1990-01-03 R-enantiomers of n-propargyl-1-aminoindan compounds, their preparation and pharmaceutical compositions containing them
IE437690A IE62371B1 (en) 1990-01-03 1990-12-04 R-enantiomers of n-propargyl-1-aminoindan compounds, their preparation and pharmaceutical compositions containing them.
HU051/90A HU215451B (hu) 1990-01-03 1990-12-04 R(+)-N-propargil-1-amino-indán, a vegyületet tartalmazó gyógyászati készítmények és előállításuk
AU67724/90A AU630772B2 (en) 1990-01-03 1990-12-04 R-enantiomers of n-propargyl-1-aminoindan compounds, their preparation and pharmaceutical compositions containing them
CA002031714A CA2031714C (en) 1990-01-03 1990-12-06 R-enantiomers of n-propargyl-1-aminoindan compounds, their preparation and pharmaceutical compositions containing them
ZA909997A ZA909997B (en) 1990-01-03 1990-12-12 R-enantiomers of n-propargyl-1-aminoindan compounds,their preparation and pharmaceutical compositions containing them
RO146581A RO107552B1 (ro) 1990-01-03 1990-12-18 Derivat de 1-aminoindan, procedeu de obtinere si compozitii farmaceutice care continind acest derivat
JP2409285A JP2987453B2 (ja) 1990-01-03 1990-12-28 Ｎ−プロパルギル−１−アミノインダン化合物のｒ（＋）−鏡像体、それらの製造法およびそれらを含有する薬剤組成物
ES91100081T ES2057604T3 (es) 1990-01-03 1991-01-02 Enantiomero r de n-propargil-1-aminoindano, su preparacion y composiciones farmaceuticas que lo contienen.
EP91100081A EP0436492B1 (en) 1990-01-03 1991-01-02 R-Enantiomer of N-propargyl-1-aminoindan, its preparation and pharmaceutical compositions containing it
AT91100081T ATE106860T1 (de) 1990-01-03 1991-01-02 R-enantiomer von n-propargyl-1-aminoindan, dessen herstellung und dieses enthaltende pharmazeutische zusammensetzungen.
SU914894485A RU2001614C1 (ru) 1990-01-03 1991-01-02 R (+)-N-Пропаргил-1-аминоиндан и его фармацевтически пригодные кислотно-аддитивные соли и фармацевтическа композици , обладающа ингибирующей B-форму фермента моноаминооксидазы активностью
DE69102288T DE69102288T2 (de) 1990-01-03 1991-01-02 R-Enantiomer von N-Propargyl-1-aminoindan, dessen Herstellung und dieses enthaltende pharmazeutische Zusammensetzungen.
DK91100081.8T DK0436492T3 (da) 1990-01-03 1991-01-02 R-Enantiomere af N-propargyl-1-aminoindanforbindelser, fremstilling deraf samt farmaceutiske præparater indeholdende disse forbindelser
SK6-91A SK280742B6 (sk) 1990-01-03 1991-01-03 R(+)-n-propargyl-1-aminoindán, spôsob jeho príprav
CS19916A CZ288222B6 (en) 1990-01-03 1991-01-03 R-Enantiomers of N-propargyl-1-aminoindane compounds, process of their preparation and pharmaceutical preparations in which they are comprised
US08/063,455 US5387612A (en) 1990-01-03 1993-05-18 Use of the R-enantiomers of N-propargyl-1-aminoindan compounds for treating Parkinson's disease
US08/198,205 US5457133A (en) 1990-01-03 1994-02-17 R-enantiomers of N-propargyl-aminoindan compounds, their preparation and pharmaceutical compositions containing them
US08/255,046 US5453446A (en) 1990-01-03 1994-06-07 Use of the R-enantiomers of N-propargyl 1-aminoindan compounds for treating Parkinson's disease.
DE200512000045 DE122005000045I1 (de) 1990-01-03 1994-07-14 R-Enantiomer von N-Propargyl-1-aminoindan, dessen Herstellung und dieses enthaltende pharmazeutischeZusammensetzungen.
US08/411,398 US5532415A (en) 1990-01-03 1995-03-28 R-enantiomer of N-propargyl-1-aminoindan, salts, compositions and uses thereof
US08/446,439 US5744500A (en) 1990-01-03 1995-05-22 Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof
US08/458,645 US5668181A (en) 1990-01-03 1995-06-02 Use of the R-enantiomers of N-propargyl-1-aminoindan compounds for the treatment of depression
US08/459,402 US5576353A (en) 1990-01-03 1995-06-02 Method of treating memory disorders using R-enantiomers of N-propargyl-aminoindan compounds
US08/465,787 US5599991A (en) 1990-01-03 1995-06-06 Esylate and sulfate salts of R(+)-N-propargyl-1-aminoindan
US08/470,161 US5786390A (en) 1990-01-03 1995-06-06 Pharmaceutical compositions of the R-enantiomer of N-propargyl -1-aminoindan
US08/466,069 US5519061A (en) 1990-01-03 1995-06-06 R-enantiomer of n-propargyl-1-aminoindan, salts, compositions and uses thereof
US08/466,250 US5891923A (en) 1990-01-03 1995-06-06 R-enantiomer of N-propargyl-1-aminoindan for the treatment of dementia
HK98107147A HK1008017A1 (en) 1990-01-03 1998-06-27 R-enantiomer of n-propargyl-1-aminoindan, its preparation and pharmaceutical compositions containing it
US10/305,478 US6956060B2 (en) 1990-01-03 2002-11-27 Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof
US11/155,864 US20060094783A1 (en) 1990-01-03 2005-06-17 Use of R-enantiomer of N-propargyl-1-aminoindan, salts, compositions and uses thereof
NL300206C NL300206I1 (nl) 1990-01-03 2005-08-16 R-enantiomeer van N-propargyl-1-aminoindaan, de bereiding daarvan en farmaceutische preparaten die dit bevatten.
LU91195C LU91195I2 (fr) 1990-01-03 2005-08-17 Rasagiline et ses sels pharmaceutiquement acceptables (AZILECT)
US11/595,726 US20070100001A1 (en) 1990-01-03 2006-11-10 Use of R-enantiomer of N-propargyl-1-aminoindan, salts, compositions and uses thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IL9295290A IL92952A (en) 1990-01-03 1990-01-03 R-enantiomers of n-propargyl-1-aminoindan compounds, their preparation and pharmaceutical compositions containing them

Publications (2)

Publication Number Publication Date
IL92952A0 IL92952A0 (en) 1990-09-17
IL92952A true IL92952A (en) 1994-06-24

Family

ID=11060756

Family Applications (1)

Application Number Title Priority Date Filing Date
IL9295290A IL92952A (en) 1990-01-03 1990-01-03 R-enantiomers of n-propargyl-1-aminoindan compounds, their preparation and pharmaceutical compositions containing them

Country Status (20)

Country Link
US (10) US5387612A (cs)
EP (1) EP0436492B1 (cs)
JP (1) JP2987453B2 (cs)
AT (1) ATE106860T1 (cs)
AU (1) AU630772B2 (cs)
CA (1) CA2031714C (cs)
CZ (1) CZ288222B6 (cs)
DE (2) DE69102288T2 (cs)
DK (1) DK0436492T3 (cs)
ES (1) ES2057604T3 (cs)
HK (1) HK1008017A1 (cs)
HU (1) HU215451B (cs)
IE (1) IE62371B1 (cs)
IL (1) IL92952A (cs)
LU (1) LU91195I2 (cs)
NL (1) NL300206I1 (cs)
RO (1) RO107552B1 (cs)
RU (1) RU2001614C1 (cs)
SK (1) SK280742B6 (cs)
ZA (1) ZA909997B (cs)

Families Citing this family (125)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL92952A (en) * 1990-01-03 1994-06-24 Teva Pharma R-enantiomers of n-propargyl-1-aminoindan compounds, their preparation and pharmaceutical compositions containing them
US5744500A (en) * 1990-01-03 1998-04-28 Teva Pharmaceutical Industries, Ltd. Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof
IL112819A (en) * 1991-10-16 2001-11-25 Teva Pharma Fluorinated 1-aminoindan compounds and a process for their preparation
IL111240A (en) * 1993-10-18 2001-10-31 Teva Pharma Salts of r(+) - enantiomers of n- propargyl-1-aminoindan and pharmaceutical compositions comprising them
US5914349A (en) * 1994-01-10 1999-06-22 Teva Pharmaceutical Industries, Ltd. Compositions containing and methods of using 1-aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives
AU1867095A (en) * 1994-01-10 1995-08-01 Technion Research & Development Foundation Ltd. 1-aminoindan derivatives and compositions thereof
US5726969A (en) * 1994-12-28 1998-03-10 Matsushita Electric Industrial Co., Ltd. Optical recording medium having dual information surfaces
ZA96211B (en) * 1995-01-12 1996-07-26 Teva Pharma Compositions containing and methods of using 1- aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives
ES2199283T5 (es) * 1995-03-02 2008-05-16 R.P. Scherer Technologies, Inc. Composiciones farmaceuticas que comprenden inhibidores de la monoamina oxidasa b.
US5679715A (en) * 1995-06-07 1997-10-21 Harris; Richard Y. Method for treating multiple sclerosis
US5646188A (en) * 1995-07-05 1997-07-08 Teva Pharmaceutical Industries, Ltd. Polyamine derivatives of 1-aminoindan
AU771490B2 (en) * 1995-09-20 2004-03-25 Teva Pharmaceutical Industries Ltd. Stable compositions containing N-propargyl-1-aminoidan
IL115357A (en) * 1995-09-20 2000-01-31 Teva Pharma Stable compositions containing N-propargyl-1-aminoindan and polyhydric alcohols
IL118836A (en) 1996-07-11 2001-01-11 Teva Pharma Pharmaceutical compositions comprising s-(-)-n-propargyl-1-aminoindan
US6043283A (en) * 1996-09-20 2000-03-28 Baylor College Of Medicine Tyramine compounds and their neuronal effects
US6191166B1 (en) 1997-11-21 2001-02-20 Elan Pharmaceuticals, Inc. Methods and compounds for inhibiting β-amyloid peptide release and/or its synthesis
US6211235B1 (en) 1996-11-22 2001-04-03 Elan Pharmaceuticals, Inc. Compounds for inhibiting β-amyloid peptide release and/or its synthesis
EP0966435B1 (en) * 1996-12-18 2005-04-06 Teva Pharmaceutical Industries, Ltd. Aminoindan derivatives
US6683075B1 (en) 1996-12-23 2004-01-27 Athena Neurosciences, Inc. Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use
US6635632B1 (en) 1996-12-23 2003-10-21 Athena Neurosciences, Inc. Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
EP1249238A3 (en) 1997-02-24 2003-03-26 S.L.A. Pharma AG Topical pharmaceutical composition comprising bethanechol
US8048875B1 (en) * 1997-02-24 2011-11-01 S.L.A. Pharma Ag Topical pharmaceutical composition comprising a cholinergic agent or a calcium channel blocker
GB9715082D0 (en) * 1997-07-17 1997-09-24 Scherer Ltd R P Treatment of attention deficit hyperactivity disorder and narcolepsy
US5866547A (en) 1998-01-20 1999-02-02 Beth Israel Deaconess Medical Center Methods of neuroendocrine regulation of affective disorders
US6509331B1 (en) 1998-06-22 2003-01-21 Elan Pharmaceuticals, Inc. Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
US6552013B1 (en) 1998-06-22 2003-04-22 Elan Pharmaceuticals, Inc. Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
US6774125B2 (en) * 1998-06-22 2004-08-10 Elan Pharmaceuticals, Inc. Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
US6569851B1 (en) 1998-06-22 2003-05-27 Elan Pharmaceutials, Inc. Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
US6528505B1 (en) 1998-06-22 2003-03-04 Elan Pharmaceuticals, Inc. Cyclic amino acid compounds pharmaceutical compositions comprising same and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
US6232326B1 (en) 1998-07-14 2001-05-15 Jodi A. Nelson Treatment for schizophrenia and other dopamine system dysfunctions
NZ512027A (en) 1998-11-10 2004-04-30 Teva Pharma Dispersible compositions containing L-dopa ethyl ester
US6506378B1 (en) * 1998-12-16 2003-01-14 Arch Development Corporation Vesicular monoamine transporter gene therapy in Parkinson's disease
US6737547B1 (en) 1998-12-31 2004-05-18 Teva Pharmaceutical Industries, Ltd. Compositions containing and methods of using N-acyl-1H-aminoindenes
AU775885B2 (en) * 1999-10-27 2004-08-19 Teva Pharmaceutical Industries Ltd. Use of 1-aminoindan derivatives for treatment of mania in bipolar mood disorder
RU2170576C1 (ru) * 1999-11-15 2001-07-20 Государственное учреждение науки Институт токсикологии Гидрохлориды замещенных ацетиленовых аминоспиртов, обладающие антигалоперидоловой активностью
US6548484B1 (en) 2000-04-12 2003-04-15 International Medical Innovations, Inc. Pharmaceutical dopamine glycoconjugate compositions and methods of their preparation
IL141690A (en) * 2001-02-27 2004-06-20 Isp Finetech Ltd Process for preparation of rasagiline and its salts
US20040010038A1 (en) * 2002-02-27 2004-01-15 Eran Blaugrund Propargylamino indan derivatives and propargylamino tetralin derivatives as brain-selective MAO inhibitors
JP4757024B2 (ja) * 2002-11-07 2011-08-24 テクニオン リサーチ アンド ディベラップメント ファウンデイション リミテッド 神経保護鉄キレート剤及びそれを含む医薬組成物
US7396860B2 (en) * 2002-11-15 2008-07-08 Teva Pharmaceutical Industries, Ltd. Use of rasagiline with or without riluzole to treat amyotrophic lateral sclerosis
US20040176430A1 (en) * 2002-11-21 2004-09-09 Jeffrey Sterling Propargyl-trifluoromethoxy-amino-benzothiazole derivatives
DK1426049T3 (da) * 2002-12-02 2005-08-22 Sanol Arznei Schwarz Gmbh Iontophoretisk tilförsel af rotigotin til behandling af Parkinsons sygdom
US20050192265A1 (en) * 2003-03-20 2005-09-01 Thompson Richard C. Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds
CA2547053C (en) * 2003-11-25 2014-05-27 Technion Research & Development Foundation Ltd. Compositions and methods for treatment of cardiovascular disorders and diseases
US8097608B2 (en) * 2003-11-25 2012-01-17 Technion Research And Development Foundation Ltd. Methods for treatment of cardiovascular disorders and diseases
JP2005232148A (ja) * 2004-02-03 2005-09-02 Technion Research & Development Foundation Ltd 神経保護剤としてプロパルギルアミンの使用
US20050197365A1 (en) * 2004-02-27 2005-09-08 Jeffrey Sterling Diamino thiazoloindan derivatives and their use
WO2006014973A2 (en) * 2004-07-26 2006-02-09 Teva Pharmaceutical Industries, Ltd. Pharmaceutical dosage forms including rasagiline
US20060025446A1 (en) * 2004-07-27 2006-02-02 Jeffrey Sterling Propargyl nitroxides and indanyl nitroxides and their use for the treatment of neurologic diseases and disorders
WO2006014968A2 (en) * 2004-07-27 2006-02-09 Teva Pharmaceutical Industries, Ltd. Propargyl nitroxydes and indanyl nitroxides and their use for the treatment of neurologic diseases and disorders
PT1848415E (pt) * 2005-02-17 2013-06-27 Teva Pharma Terapia de combinação com acetato de glatirâmero e rasagilina para o tratamento da esclerose múltipla
US20100167983A1 (en) * 2007-10-22 2010-07-01 Teva Pharmaceutical Industries, Ltd. Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis
CA2600008A1 (en) * 2005-02-22 2006-11-16 Teva Pharmaceutical Industries Ltd. Improved process for the synthesis of enantiomeric indanylamine derivatives
KR20170023211A (ko) 2005-02-23 2017-03-02 테바 파마슈티컬 인더스트리즈 리미티드 함량 균일성이 개선된 라사길린 제형
WO2006091836A1 (en) * 2005-02-24 2006-08-31 Teva Pharmaceutical Industries, Ltd. Formulations of ladostigil tartrate
EP1890690A4 (en) * 2005-06-02 2010-06-02 Jenrin Discovery MAO-B-HEMMER FOR THE TREATMENT OF FAT
US8263655B2 (en) 2005-10-06 2012-09-11 Technion Research And Development Foundation Ltd Methods for treatment of renal failure
WO2007061717A2 (en) 2005-11-17 2007-05-31 Teva Pharmaceutical Industries, Ltd. Methods for isolating propargylated aminoindans
US7572834B1 (en) 2005-12-06 2009-08-11 Teva Pharmaceutical Industries, Ltd. Rasagiline formulations and processes for their preparation
US20070135518A1 (en) * 2005-12-09 2007-06-14 Marta Weinstock-Rosin Use of low-dose ladostigil for neuroprotection
EP1956904B1 (en) 2005-12-09 2017-04-12 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Low-dose ladostigil for the treatment of mild cognitive impairment
CN1990455B (zh) * 2005-12-29 2011-06-08 北京德众万全医药科技有限公司 一种简单、新颖的茚衍生物的制备方法
JP5701485B2 (ja) 2006-02-21 2015-04-15 テバ ファーマシューティカル インダストリーズ リミティド 多系統萎縮症の治療のためのラサギリンの使用
TW200744576A (en) 2006-02-24 2007-12-16 Teva Pharma Propargylated aminoindans, processes for preparation, and uses thereof
US20070232691A1 (en) * 2006-03-31 2007-10-04 Tamar Goren Use of ladostigil for the treatment of schizophrenia
JP5769923B2 (ja) 2006-04-03 2015-08-26 テバ ファーマシューティカル インダストリーズ リミティド レストレスレッグス症候群の治療のためのラサギリンの使用
ES2412384T3 (es) * 2006-07-18 2013-07-11 Astellas Pharma Inc. Derivado de aminoindano o sal del mismo
EP1892233A1 (de) * 2006-08-18 2008-02-27 Ratiopharm GmbH Neue Salze des Wirkstoffs Rasagilin
AU2007334428B2 (en) * 2006-12-14 2014-05-29 Teva Pharmaceutical Industries, Ltd. Crystalline solid rasagiline base
KR101077835B1 (ko) * 2006-12-14 2011-10-28 테바 파마슈티컬 인더스트리즈 리미티드 라사길린의 타닌산염
EP1987816A1 (de) * 2007-04-30 2008-11-05 Ratiopharm GmbH Adsorbate eines Rasagilinsalzes mit einem wasserlöslichen Hilfsstoff
AU2008296908B2 (en) * 2007-09-05 2014-01-09 Teva Pharmaceutical Industries, Ltd. Method of treating glaucoma using rasagiline
US8188149B2 (en) * 2007-09-17 2012-05-29 Teva Pharmaceutical Industries, Ltd. Use of R(+)-N-propargy1-1-aminoindan to treat or prevent hearing loss
US8461388B2 (en) 2007-12-24 2013-06-11 Cipla Limited Process for the synthesis of propargylated aminoindan derivatives
SG187455A1 (en) * 2008-01-11 2013-02-28 Teva Pharma Rasagiline formulations, their preparation and use
US20090247537A1 (en) * 2008-03-25 2009-10-01 William Dale Overfield Methods for preventing or treating bruxism using dopaminergic agents
EP2271612B1 (en) * 2008-03-31 2016-08-10 Actavis Group PTC EHF Rasagiline mesylate particles and process for the preparation thereof
WO2009141737A2 (en) * 2008-05-23 2009-11-26 Medichem, S.A. A new method for obtaining an aminoindan mesylate derivative
PL2285769T3 (pl) 2008-06-02 2015-01-30 Generics Uk Ltd Sposób otrzymywania enancjomerycznie czystych amin
US20110184071A1 (en) * 2008-06-02 2011-07-28 Vinayak Gore process for the preparation of amines
US20100008983A1 (en) * 2008-06-10 2010-01-14 Muhammad Safadi Rasagiline soft gelatin capsules
EA201170018A1 (ru) * 2008-06-13 2011-08-30 Тева Фармасьютикал Индастриз, Лтд. Разагилин для изменения течения болезни паркинсона
JP2011524907A (ja) 2008-06-19 2011-09-08 テバ ファーマシューティカル インダストリーズ リミティド 固体ラサギリン塩基を調製および乾燥する方法
JP2011525489A (ja) * 2008-06-19 2011-09-22 テバ ファーマシューティカル インダストリーズ リミティド ラサリジン塩基の精製方法
EA201170181A1 (ru) 2008-07-11 2011-08-30 Синтон Бв Полиморфные формы разагилина гидрохлорида
US20100029987A1 (en) * 2008-07-29 2010-02-04 Dipharma Francis S.R.I. Crystalline Form of Rasagiline and Process for the Preparation Thereof
IT1392914B1 (it) * 2009-01-22 2012-04-02 Dipharma Francis Srl Procedimento per la preparazione di (r)-n-propargil-1-amminoindano e suoi sali
EP2181980A1 (en) 2008-10-28 2010-05-05 Chemo Ibérica, S.A. A process for the preparation of (R)-1-aminoindanes
EP2358658A4 (en) * 2008-11-20 2012-11-14 Reddys Lab Ltd Dr PREPARATION OF RASAGILIN AND ITS SALTS
DE102008064061A1 (de) 2008-12-19 2010-06-24 Ratiopharm Gmbh Feste Zusammensetzung mit dem Wirkstoff Rasagilin
EP2218444A3 (en) 2009-01-23 2010-08-25 Teva Pharmaceutical Industries, Ltd. Delayed release rasagiline formulation
US20100189791A1 (en) * 2009-01-23 2010-07-29 Teva Pharmaceutical Industries, Ltd. Delayed release rasagiline malate formulation
WO2010100219A2 (en) 2009-03-05 2010-09-10 Sandoz Ag Pharmaceutical composition containing 1h-inden-1-amine, 2,3-dihydro-n-2-propynyl-, (1r)-, methanesulfonate
PL2451771T3 (pl) 2009-07-09 2014-12-31 Ratiopharm Gmbh Sole rasagiliny i ich preparaty farmaceutyczne
WO2011048612A2 (en) * 2009-10-14 2011-04-28 Glenmark Generics Limited Processes for the preparation of propargylated aminoindans or a pharmaceutically acceptable salt thereof
EP2325159A1 (en) 2009-11-24 2011-05-25 LEK Pharmaceuticals d.d. Novel salts of rasagiline
US8741962B2 (en) 2009-11-26 2014-06-03 Usv Limited Process for preparation of Rasagiline and salts thereof
US20110152381A1 (en) * 2009-12-22 2011-06-23 Anton Frenkel 3-keto-n-propargyl-1-aminoindan
US20120269871A1 (en) 2009-12-30 2012-10-25 Actavis Group Ptc Ehf Solid state forms of rasagiline salts
WO2011095985A2 (en) * 2010-02-02 2011-08-11 Glenmark Generics Limited Rasagiline salts and processes for the preparation thereof
KR101791715B1 (ko) 2010-02-03 2017-10-30 파마 투 비 엘티디 라사길린의 연장 방출 제형 및 그 용도
WO2011121607A2 (en) 2010-03-29 2011-10-06 Cadila Healthcare Limited Rasagiline and its pharmaceutically acceptable salts
EP2563347B1 (en) 2010-04-30 2016-10-12 Teikoku Pharma USA, Inc. Propynylaminoindan transdermal compositions
EP2389927A1 (en) 2010-05-30 2011-11-30 Abdi Ibrahim Ilac Sanayi ve Ticaret Anonim Sirketi Pharmaceutical formulations of rasagiline
AU2011282720B2 (en) 2010-07-27 2016-12-22 Teva Pharmaceutical Industries Ltd. Use of rasagiline for the treatment of olfactory dysfunction
JP2013537530A (ja) 2010-07-27 2013-10-03 テバ ファーマシューティカル インダストリーズ リミティド ラサギリンシトレートの分散物
PH12013500821A1 (en) * 2010-10-26 2019-07-03 Teva Pharma Deuterium enriched rasagiline
WO2012096635A1 (en) 2011-01-13 2012-07-19 Fargem Farmasöti̇k Araştirma Geli̇şti̇rme Merkezi̇ Sanayi̇ Ve Ti̇caret A.Ş. A new method for the synthesis of rasagiline
WO2012116752A1 (en) 2011-03-03 2012-09-07 Synthon Bv Process of resolution of 1-aminoindan
US9119799B2 (en) 2011-03-24 2015-09-01 Teikoku Pharma Usa, Inc. Transdermal compositions comprising an active agent layer and an active agent conversion layer
WO2012153349A2 (en) 2011-05-04 2012-11-15 Cadila Healthcare Limited Rasagiline and its pharmaceutically acceptable salts
JP2014534196A (ja) 2011-10-10 2014-12-18 テバ ファーマシューティカル インダストリーズ リミティド Ｒ（＋）−ｎ−ホルミル−プロパルギル−アミノインダン
MX2014004201A (es) 2011-10-10 2015-01-12 Teva Pharma R(+)-n-metil-propargil-aminoindano.
JP5913614B2 (ja) 2011-11-09 2016-04-27 テイコク ファーマ ユーエスエー インコーポレーテッド 皮膚新生物の処置方法
EP2610239A1 (en) 2012-01-02 2013-07-03 Dr. Reddy's Laboratories Ltd. Preparation Of Rasagiline Hemitartrate
DE102012000786A1 (de) 2012-01-18 2013-07-18 Stada Arzneimittel Ag Verfahren zur Herstellung einer festen pharmazeutischen Zusammensetzung, enthaltend den Wirkstoff Rasagilin
ES2584059T3 (es) 2012-03-21 2016-09-23 Synthon Bv Composiciones farmacéuticas estabilizadas que comprenden sales de rasagilina
WO2013175493A1 (en) 2012-04-09 2013-11-28 Cadila Healthcare Limited Stable oral pharmaceutical compositions
BR112015003451A2 (pt) 2012-08-17 2017-07-04 Teva Pharma formulação parentérica de rasagilina
US9205061B2 (en) 2012-11-02 2015-12-08 Teikoku Pharma Usa, Inc. Propynylaminoindan transdermal compositions
EP2796130A3 (en) 2013-02-06 2015-02-25 Galenicum Health S.L. Immediate release tablets of rasagiline hemitartrate
EP2764862A1 (en) 2013-02-06 2014-08-13 Galenicum Health S.L. Immediate release tablets of rasagiline hemitartrate
EP2968222A4 (en) * 2013-03-13 2016-10-19 N To B Ltd METHOD, COMPOSITIONS AND DEVICES FOR TREATING MOTOR DISTURBANCES AND DEPRESSION SYMPTOMS RELATED TO MORBUS PARKINSON
WO2015136515A1 (en) * 2014-03-13 2015-09-17 Abital Pharma Pipelines Ltd. Methods, compositions and devices for treatment of motor and depression symptoms associated with parkinson's disease
CN111333517A (zh) * 2018-12-19 2020-06-26 上海奥博生物医药技术有限公司 一种制备雷沙吉兰的改进方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3201470A (en) * 1965-08-17 Chsx c cech
FR1366728A (fr) * 1961-03-01 1964-07-17 Roussel Uclaf Nouveaux dérivés du gonane et leur procédé de préparation
US3253037A (en) * 1962-06-19 1966-05-24 Ciba Geigy Corp N-2-alkynyl-amino-benzocylo-alkanes
GB1187017A (en) * 1966-07-16 1970-04-08 Aspro Nicholas Ltd Substituted 1-Amino Indanes and Tetrahydronaphthalens
GB1037014A (en) * 1963-08-02 1966-07-20 Aspro Nicholas Ltd Derivatives of 1-aminoindane
US3513249A (en) * 1968-12-24 1970-05-19 Ideal Ind Explosion connector with improved insulating means
DE3779500T2 (de) * 1986-06-10 1993-01-21 Chiesi Farma Spa Levodopa-methyl-ester enthaltende pharmazeutische zusammensetzungen, ihre herstellung und therapeutische verwendungen.
JPH03176457A (ja) * 1989-12-04 1991-07-31 Nippon Paint Co Ltd 新規プロパルギル化合物、その製法ならびに該化合物を含む被覆材
IL92952A (en) * 1990-01-03 1994-06-24 Teva Pharma R-enantiomers of n-propargyl-1-aminoindan compounds, their preparation and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
DE122005000045I1 (de) 2005-12-22
US5599991A (en) 1997-02-04
US5387612A (en) 1995-02-07
US5457133A (en) 1995-10-10
US5532415A (en) 1996-07-02
DE69102288D1 (de) 1994-07-14
HUT59376A (en) 1992-05-28
EP0436492A3 (en) 1991-11-13
RU2001614C1 (ru) 1993-10-30
DK0436492T3 (da) 1994-07-11
AU6772490A (en) 1991-07-04
HU908051D0 (en) 1991-06-28
ATE106860T1 (de) 1994-06-15
LU91195I2 (fr) 2005-10-17
AU630772B2 (en) 1992-11-05
US5453446A (en) 1995-09-26
CA2031714C (en) 1998-08-25
CS691A3 (en) 1991-08-13
CZ288222B6 (en) 2001-05-16
ES2057604T3 (es) 1994-10-16
JP2987453B2 (ja) 1999-12-06
EP0436492A2 (en) 1991-07-10
US5576353A (en) 1996-11-19
US5668181A (en) 1997-09-16
US5891923A (en) 1999-04-06
IE904376A1 (en) 1991-07-03
DE69102288T2 (de) 1995-02-09
CA2031714A1 (en) 1991-07-04
IE62371B1 (en) 1995-01-25
ZA909997B (en) 1991-10-30
RO107552B1 (ro) 1993-12-30
HK1008017A1 (en) 1999-04-30
IL92952A0 (en) 1990-09-17
SK280742B6 (sk) 2000-07-11
US5786390A (en) 1998-07-28
US5519061A (en) 1996-05-21
NL300206I1 (nl) 2005-10-03
EP0436492B1 (en) 1994-06-08
HU215451B (hu) 2000-10-28
JPH03294248A (ja) 1991-12-25

Similar Documents

Publication Publication Date Title
CA2031714C (en) R-enantiomers of n-propargyl-1-aminoindan compounds, their preparation and pharmaceutical compositions containing them
HK1008017B (en) R-enantiomer of n-propargyl-1-aminoindan, its preparation and pharmaceutical compositions containing it
EP0812190B1 (en) R-enantiomer of n-propargyl-1-aminoindan for the treatment of various diseases and mesylate, esylate and sulfate thereof
AU699090B2 (en) Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof

Legal Events

Date Code Title Description
KB Patent renewed
RH Patent void
NE Application for restoration - patent lapsed through non-payment of renewal fees (section 60, patents law, 5727-1967)
KB Patent renewed
KB Patent renewed
EXTP Application for extension order is pending
KB Patent renewed
PEL Intention of commissioner to extend period of protection
EXTG Extension of patent term granted
EXTN Extension order renewed
EXTN Extension order renewed
EXTN Extension order renewed
EXTN Extension order renewed